Edition:
United States

Fresenius SE & Co KGaA (FREG.DE)

FREG.DE on Xetra

64.26EUR
11:35am EDT
Change (% chg)

€-0.92 (-1.41%)
Prev Close
€65.18
Open
€65.30
Day's High
€65.70
Day's Low
€64.10
Volume
973,498
Avg. Vol
1,308,784
52-wk High
€72.76
52-wk Low
€58.96

Chart for

About

Fresenius SE & Co KGaA is a Germany-based healthcare group. It operates through four business segments. Fresenius Medical Care runs a global network of dialysis clinics, providing treatment for patients with chronic kidney failure. It also offers dialyzers, dialysis machines and renal pharmaceuticals. Fresenius Kabi specializes... (more)

Overall

Beta: 0.56
Market Cap(Mil.): €39,028.29
Shares Outstanding(Mil.): 554.54
Dividend: 0.62
Yield (%): 0.88

Financials

  FREG.DE Industry Sector
P/E (TTM): 22.53 28.42 32.76
EPS (TTM): 3.12 -- --
ROI: 9.33 6.87 14.61
ROE: 14.09 10.80 16.33

Akorn row overshadows Fresenius' generics guidance

BERLIN Fears that a legal dispute with U.S. drugmaker Akorn could extend into next year overshadowed improved guidance from Germany's Fresenius SE for its Kabi generics business.

Jul 31 2018

UPDATE 3-Akorn row overshadows Fresenius' generics guidance

* CEO says expect case to be resolved by early 2019 (Adds CEO comments from analyst call)

Jul 31 2018

Fresenius nudges up Kabi earnings guidance

BERLIN, July 31 Fresenius SE nudged up its earnings guidance for its Kabi generics unit on Tuesday as it posted a 3 percent rise in adjusted group net profit in the second quarter.

Jul 31 2018

Cultural mix a hidden weapon in Nestle CEO's activist defense

LONDON Growing up in Germany, Mark Schneider was pushed to become fluent in English by his father, who believed it would give him an edge.

Jul 06 2018

Cultural mix a hidden weapon in Nestle CEO's activist defence

LONDON Growing up in Germany, Mark Schneider was pushed to become fluent in English by his father, who believed it would give him an edge.

Jul 06 2018

Fresenius transfers inpatient rehabilitation business to Vamed unit

FRANKFURT, June 6 German healthcare group Fresenius said it was transferring its inpatient rehabilitation business from its private hospital operations to its Fresenius Vamed unit to better enable continued growth at the two businesses.

Jun 06 2018

Fresenius CEO defends canceled Akorn deal

FRANKFURT/BERLIN Fresenius SE's chief executive has defended the company's decision to pull out of a planned $4.8 billion takeover of Akorn , saying it was the only option after uncovering data integrity breaches at the U.S drugmaker.

May 18 2018

UPDATE 1-Fresenius CEO defends cancelled Akorn deal

* Expects legal proceedings to conclude in 2019 (Adds details on expenses, comment on provision, analyst)

May 18 2018

BRIEF-Fresenius Costs Related To Akorn Total 60 Mln Euros So Far - CEO

* CEO SAYS COSTS RELATED TO AKORN TRANSACTION TOTAL 60 MILLION EUROS SO FAR

May 18 2018

Fresenius CEO defends cancelled Akorn deal

FRANKFURT/BERLIN, May 18 Fresenius SE's chief executive has defended the company's decision to pull out of a planned $4.8 billion takeover of Akorn, saying it was the only option after uncovering data integrity breaches at the U.S drugmaker.

May 18 2018

Earnings vs. Estimates